Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors

Background: Atezolizumab has been studied in multiple indications for both pediatric and adult patient populations. Generally, clinical studies enrolling pediatric patients may not collect sufficient pharmacokinetic data to characterize the drug exposure and disposition because of operational, ethic...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Weize Huang, Felix Stader, Phyllis Chan, Colby S. Shemesh, Yuan Chen, Katherine L. Gill, Hannah M. Jones, Linzhong Li, Gianluca Rossato, Benjamin Wu, Jin Y. Jin, Pascal Chanu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2022-09-01
coleção:	Frontiers in Pharmacology
Assuntos:	alveolar soft part sarcoma atezolizumab physiologically-based pharmacokinetic (PBPK) modeling pediatric extrapolation pediatric oncology solid tumor
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fphar.2022.974423/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!